高风险神经母细胞瘤 (LEAHRN) 后的晚期影响:来自儿童瘤学组的多中心,横截面队列研究
Tara O Henderson1, Jenna K Bardwell1, Pei-Chi Kao2
1Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, IL, USA.
The Lancet. Child & adolescent health
|September 28, 2025
概括
高风险神经母细胞瘤的幸存者面临现代治疗的显著晚期影响,包括听力损失和生长失败. 双重干细胞移植增加了生长衰竭和限制性肺病的风险,影响了长期的健康结果.
科学领域:
- 儿科瘤学 儿科瘤学
- 癌症的生存率 癌症的生存率
- 临床研究 临床研究
背景情况:
- 现代神经母细胞瘤治疗改善了儿童的生存率.
- 这些疗法的晚期影响还不太清楚.
- 这项研究调查了晚期效应的治疗相关风险因素.
研究的目的:
- 探索与治疗相关的风险因素,以研究高风险神经母细胞瘤幸存者的晚期影响.
- 为了确定与现代癌症疗法相关的特定毒性.
- 为未来的临床试验设计和患者护理提供信息.
主要方法:
- 在375名高风险神经母细胞瘤幸存者 (诊断≥2000) 的多中心,横截面队列研究中.
- 评估包括听力测量,肺功能测试,心声图和实验室研究.
- 多变量逻辑回归分析了治疗暴露和晚期影响 (听力损失,生长不良,体重不足,限制性肺病) 之间的关联.
主要成果:
- 晚期影响的高患病率:72%的听力损失,24%的生长不良,51%的体重不足,8%的限制性肺病.
- 长时间的随访与晚期效应流行率的增加相关.
- 串联干细胞移植 (与单个) 增加了生长衰竭 (OR 3.4) 和限制性肺病 (OR 4.5) 的风险.
结论:
- 高风险神经母细胞瘤幸存者经历了大量的后期效应负担.
- 双重干细胞移植是特定晚期效应的危险因素.
- 这些发现对于优化对神经母细胞瘤幸存者的未来护理和临床试验设计至关重要.
更多相关视频
13:12Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
Published on: August 12, 2019
46.3K
09:33Neuronavigated Focalized Transcranial Direct Current Stimulation Administered During Functional Magnetic Resonance Imaging
Published on: November 15, 2024
2.0K
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
